Close
FINDING CURES TOGETHER<sup>SM</sup>

Pediatric Cancer Working Group at the Annual Meeting

The annual meeting is an extraordinary venue that fosters scientific discussions and helps build bridges across various disciplines. We encourage all meeting attendees to take advantage of the opportunities presented at the meeting to learn about the latest advances in pediatric cancer research, attend sessions outside your own areas of expertise and network with other scientists and clinicians interested in pediatric oncology.

*Follow the link below to view this year's AACR Annual Meeting Pediatric Oncology Sessions Track Book (Adobe Reader required).

AM2015 Pediatric Oncology Track Book.pdf


AACR Annual Meeting 2015 - Pediatric Cancer Working Group Highlights


2nd Annual Advocacy Partners Pavilion
 
The pavilion is a designated area on the Annual Meeting exhibit show floor where not-for-profit cancer patient advocacy organizations can educate annual meeting attendees and network among groups, patients, and health care professionals.

Pediatric Cancer Organizations Scheduled to Participate:
Children's Cause for Cancer Advocacy
Kids v Cancer


AACR Pediatric Cancer Working Group Town Hall Meeting and Networking Reception
Sunday, April 19, 2015, 6:30 - 9:00 pm ET
Regency Ballroom C (Second Floor), Loews Philadelphia Hotel

All attendees of the AACR Annual Meeting are invited to attend this town hall meeting and networking reception hosted by the AACR Pediatric Cancer Working Group. In addition to open discussion and a networking reception, this meeting consists of an interactive summary of AACR's past, present, and future pediatric oncology-related initiatives, as well as recognition of the Pediatric Cancer Working Group's leadership and sponsors.


Meet the AACR Pediatric Cancer Working Group Chairperson, Lee J. Helman, MD
Monday, April 20, 2015, 10:00 - 11:00 am ET
AACRcentral, AACR Amphitheater, Halls B-E

Dr. Lee Helman is the Scientific Director for Clinical Research in the Center for Cancer Research at the National Cancer Institute and Professor of Pediatrics and Oncology at Johns Hopkins University. His tenure at NCI began with a fellowship after receiving his MD from the University Of Maryland School Of Medicine and completing his residency at Barnes Hospital, Washington University. Throughout his 31 years at NCI, Dr. Helman has served as Head, and later Chief of the Molecular Oncology section of the Pediatric Oncology Branch, assuming the role of Scientific Director in 2007. 

Dr. Helman’s laboratory currently focuses on three major themes related to the biology and treatment of pediatric sarcomas, specifically rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, and pediatric gastrointestinal stromal tumors (GIST). These themes are: (1) determining the pathophysiologic consequences of IGF signaling; (2) identifying the molecular/biochemical determinants of the biology of these sarcomas; and (3) applying preclinical laboratory findings to develop novel clinical studies for these sarcomas. In 2011, he was awarded the Pediatric Oncology Award and Statesman Award for his scientific achievements in the field of pediatric oncology by the American Society of Clinical Oncology (ASCO). He has been elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He serves on the Board of Directors of and is a clinical advisor to The Children’s Inn at NIH and is a past member of the NIH Advisory Board for Clinical Research, as well as the ASCO Board of Directors and Bylaws Committee. He also serves on the Scientific Advisory Committee of the Children’s Oncology Group (COG).
    
Dr. Helman has been actively involved with the American Association for Cancer Research (AACR) for many years. He has served on the AACR’s Science Education, Publications, and Clinical and Translational Cancer Research Standing Committees and has also served as Chairperson of the inaugural QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research Scientific Review Committee. He serves on the Scientific Advisory Committee of Stand Up To Cancer and has also served as an associate editor for the journals Cancer Research and Clinical Cancer Research. Dr. Helman has actively led AACR’s pediatric oncology-related initiatives since the formation of the AACR Pediatric Oncology Task Force in 2009. In 2011, Dr. Helman oversaw the evolution of this task force into the AACR Pediatric Cancer Scientific Working Group, whose membership now consists of over 1,800 members.


Fourth Annual AACR-PCWG Special Scientific Session: Optimizing Targeted Therapy Avenues for Pediatric Cancers
Tuesday, April 21, 2015, 10:30 am - 12:30 pm ET
Room 126, Pennsylvania Convention Center

All meeting attendees are invited to attend this special Pediatric Cancer Working Group sponsored event showcasing cutting-edge pediatric cancer-based research.
Moderator:
Lee J. Helman, MD, National Cancer Institute

Speakers:
David M. Langenau, PhD, Harvard Medical School
Novel oncogenic drivers in T cell acute lymphoblastic leukemia

Brenda J. Weigel, MD, University of Minnesota
New Agent Development in Pediatric Oncology: Hitting the Target

Garrett M. Brodeur, MD, Children's Hospital of Philadelphia
Nanoparticle Drug Delivery in a Mouse Model of Neuroblastoma

Michael C. Jensen, MD, Seattle Children's Research Institute
Advancing CAR T cell immunotherapy in Pediatric Oncology


Access the links below to view previous PCWG annual meeting events:


For more information, contact:
Michael J. Powell, PhD
Senior Program Administrator, Executive Office
Staff Liaison, AACR Pediatric Cancer Scientific Working Group
Phone: (215) 440-9373
Email: Michael.Powell@aacr.org